Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG CLASS:

TLR8 agonist

DRUG CLASS:

TLR8 agonist

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Related drugs:

No biomarker	Basal Cell Carcinoma	No biomarker	Basal Cell Carcinoma	imiquimod Sensitive: A1 - Approval imiquimod Sensitive : A1	imiquimod Sensitive: A1 - Approval imiquimod Sensitive : A1
No biomarker	Penile Cancer	No biomarker	Penile Cancer	imiquimod Sensitive: A2 - Guideline imiquimod Sensitive : A2	imiquimod Sensitive: A2 - Guideline imiquimod Sensitive : A2
No biomarker	Bowens Disease	No biomarker	Bowens Disease	imiquimod Sensitive: A2 - Guideline imiquimod Sensitive : A2	imiquimod Sensitive: A2 - Guideline imiquimod Sensitive : A2
No biomarker	Cutaneous Melanoma	No biomarker	Cutaneous Melanoma	imiquimod Sensitive: A2 - Guideline imiquimod Sensitive : A2	imiquimod Sensitive: A2 - Guideline imiquimod Sensitive : A2
HER-2 amplification	Solid Tumor	HER-2 amplification	Solid Tumor	SBT6050 Sensitive: C2 – Inclusion Criteria SBT6050 Sensitive : C2	SBT6050 Sensitive: C2 – Inclusion Criteria SBT6050 Sensitive : C2
HER-2 expression	Solid Tumor	HER-2 expression	Solid Tumor	SBT6050 Sensitive: C2 – Inclusion Criteria SBT6050 Sensitive : C2	SBT6050 Sensitive: C2 – Inclusion Criteria SBT6050 Sensitive : C2
NECTIN4 expression	Solid Tumor	NECTIN4 expression	Solid Tumor	SBT6290 Sensitive: C2 – Inclusion Criteria SBT6290 Sensitive : C2	SBT6290 Sensitive: C2 – Inclusion Criteria SBT6290 Sensitive : C2
HER-2 expression	Solid Tumor	HER-2 expression	Solid Tumor	BDC-1001 Sensitive: C2 – Inclusion Criteria BDC-1001 Sensitive : C2	BDC-1001 Sensitive: C2 – Inclusion Criteria BDC-1001 Sensitive : C2
HER-2 amplification	Solid Tumor	HER-2 amplification	Solid Tumor	pembrolizumab + SBT6050 Sensitive: C3 – Early Trials pembrolizumab + SBT6050 Sensitive : C3	pembrolizumab + SBT6050 Sensitive: C3 – Early Trials pembrolizumab + SBT6050 Sensitive : C3
HER-2 expression	Solid Tumor	HER-2 expression	Solid Tumor	pembrolizumab + SBT6050 Sensitive: C3 – Early Trials pembrolizumab + SBT6050 Sensitive : C3	pembrolizumab + SBT6050 Sensitive: C3 – Early Trials pembrolizumab + SBT6050 Sensitive : C3
HER-2 expression	Solid Tumor	HER-2 expression	Solid Tumor	nivolumab + BDC-1001 Sensitive: C3 – Early Trials nivolumab + BDC-1001 Sensitive : C3	nivolumab + BDC-1001 Sensitive: C3 – Early Trials nivolumab + BDC-1001 Sensitive : C3
TLR8 overexpression	Squamous Cell Carcinoma of Head and Neck	TLR8 overexpression	Squamous Cell Carcinoma of Head and Neck	cetuximab + VTX 2337 Sensitive: D – Preclinical cetuximab + VTX 2337 Sensitive : D	cetuximab + VTX 2337 Sensitive: D – Preclinical cetuximab + VTX 2337 Sensitive : D
CEACAM5 expression	Solid Tumor	CEACAM5 expression	Solid Tumor	BDC-2034 Sensitive: D – Preclinical BDC-2034 Sensitive : D	BDC-2034 Sensitive: D – Preclinical BDC-2034 Sensitive : D